KNSA

Kiniksa Pharmaceuticals International Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↑ 9/10
  • Value↓ 2/10
Kiniksa Pharmaceuticals International sales and earnings growth
KNSA Growth
Great
  • Revenue Y/Y↑ 60.09%
  • EPS Y/Y↑ 233.33%
  • FCF Y/Y↑ 436.29%
Kiniksa Pharmaceuticals International gross and profit margin trends
KNSA Profitability
Great
  • Gross margin ↑ 88.50%
  • EPS margin↓ 8.70%
  • ROIC 5Y↑ 2.42%
Kiniksa Pharmaceuticals International net debt vs free cash flow
KNSA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Kiniksa Pharmaceuticals International stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗